Korjuny (catumaxomab)
- Region
- 🇪🇺 EU
- Active substance
- catumaxomab
- Company
- Atnahs Pharma Netherlands B.V.
- Status
- Authorised
- Therapeutic area
- Ascites
- CHMP opinion
- Thu 17 Oct 2024
- EU approval
- Mon 10 Feb 2025
- Application
- EMEA/H/C/005697
- ATC
- L01FX03
- Official record
- www.ema.europa.eu
Indication
Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Removab Withdrawn · Neovii Biotech GmbH
Follow Korjuny
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.